Apoaequorin

Apoaequorin is the protein, or apoprotein, portion of aequorin, a photoprotein from the jellyfish Aequorea victoria. On its own apoaequorin does not glow; combined with a small molecule called coelenterazine and oxygen it reconstitutes active aequorin. The protein carries EF-hand motifs, structural pockets that bind calcium ions, and when calcium binds, the complex reacts and emits a flash of blue light ^[1].

Aequorin was first isolated in the early 1960s by Osamu Shimomura, whose work on the jellyfish's luminous proteins also led to the discovery of green fluorescent protein and was recognized with a share of the 2008 Nobel Prize in Chemistry. Because its light output tracks calcium concentration, aequorin, and by extension apoaequorin, became a valuable reporter for measuring calcium signaling inside living cells ^[1].

Apoaequorin is marketed by Quincy Bioscience as the active ingredient of Prevagen, a dietary supplement promoted for memory and mild age-related cognitive decline. Independent assessments have been skeptical of these claims. A review in a drug bulletin and an analysis in a pharmacy journal each concluded that the clinical evidence is limited and does not convincingly support a memory benefit ^[2][3].

The company's own clinical study, the Madison Memory Study, did not show an overall benefit over placebo on its primary measures, and critics have noted reliance on selected subgroup findings. In 2017 the United States Federal Trade Commission and the New York Attorney General charged the marketers with false and deceptive advertising ^[3]. A further scientific objection is that apoaequorin is a protein, which would be expected to be broken down into amino acids during digestion rather than reaching the brain intact.

As a dietary supplement, apoaequorin is not evaluated or approved as a drug. Its established, non-controversial role remains as a laboratory reagent for detecting calcium, in contrast to its contested use as a memory aid.

It appears generally well tolerated in the short term, with mild complaints like headache or dizziness reported. As a novel protein, allergic potential cannot be fully ruled out. The bigger issue is spending money on something with little evidence of benefit rather than a safety hazard.